



Background

- Candidate for Major Depressive Disorder, Alzheimer's & Dementias
- N-methyl-D-aspartate receptor (NMDAR) positive allosteric modulator (PAMs)
- Boosts synaptic plasticity
- FDA granted Fast-Track designation based on Phase 1/2a efficacy and Safety data for MDD
- Currently in a 164-patient Phase 2b clinical trial, started in February 2025 for MDD
- In Phase 1 for Alzheimer's and Disease-Related Dementias



Burgdorf, J. S., *Int J Neuropsychopharmacol*, **2022**, 25, 979 <https://doi.org/10.1093/ijnp/pyac043>

Route 1 (2018):



Route 2 (2020):

